Renal transplant recipients face an increased lifetime risk of developing various malignancies due to persistent immunosuppression. While carcinomas and lymphomas represent the most common post-transplant neoplasms, primary soft tissue sarcomas remain exceptionally rare. Specifically, the development of renal allograft myxofibrosarcoma represents an unprecedented clinical scenario in transplant medicine. A recent report detailed the unique emergence of this mesenchymal tumor within a nonfunctioning kidney graft twenty-five years after transplantation. Consequently, clinicians must recognize atypical mass lesions in quiescent allografts to ensure timely intervention and optimal patient recovery.

Clinical Presentation of Renal Allograft Myxofibrosarcoma

In this extraordinary case, a 74-year-old male with a history of kidney transplantation presented for routine medical evaluation. Notably, the patient had developed non-Hodgkin lymphoma earlier in his life, which clinicians had treated successfully. His renal allograft had stopped functioning years prior, leaving him on chronic renal replacement therapy. Because the patient reported no constitutional symptoms, pain, or hematuria, the discovery of the intra-graft lesion occurred incidentally during abdominal surveillance imaging. Nonfunctioning allografts often undergo progressive atrophy, fibrous involution, and chronic calcification over decades. However, the emergence of an expanding soft tissue lesion within a quiescent graft always demands immediate investigation. Clinicians initially suspected chronic graft rejection or a secondary lymphomatous recurrence due to his oncologic history. Furthermore, mesenchymal neoplasms rarely enter the initial differential diagnosis because they account for less than one percent of renal malignancies. Therefore, incidental cross-sectional findings in failed allografts necessitate comprehensive multiplanar imaging before surgical planning.

Diagnostic Imaging and Preoperative Evaluation

Accurate preoperative imaging plays a decisive role in identifying solid mass lesions within failed kidney grafts. Contrast-enhanced computed tomography typically reveals heterogeneous mass enhancement, irregular parenchymal distortion, and peripheral infiltrative margins. In this patient, clinicians performed contrast-enhanced abdominal computed tomography alongside advanced magnetic resonance imaging to evaluate the renal mass. Magnetic resonance imaging excels at distinguishing myxoid matrices, which demonstrate characteristic high signal intensity on T2-weighted sequences. Additionally, post-contrast sequences typically show gradual, nodular, or peripheral enhancement within the gelatinous tumor matrix. These multiplanar modalities also evaluate vascular invasion, retroperitoneal lymphadenopathy, and adjacent organ involvement. Because primary graft malignancies often mimic chronic hematomas or abscesses, radiological vigilance remains essential. Furthermore, cross-sectional imaging provides surgeons with critical anatomic roadmaps before reoperative pelvic exploration. Prompt radiological differentiation prevents unneeded percutaneous biopsies that might seed malignant mesenchymal cells along the retroperitoneal needle tract. Moreover, comprehensive chest imaging rules out synchronous pulmonary metastases, which represent the most common metastatic destination for soft tissue sarcomas. Consequently, the surgical team scheduled an elective allograft nephrectomy to achieve definitive histopathological clearance.

Histopathological Characteristics and Differential Diagnosis

Following surgical excision, pathological examination established the definitive diagnosis of primary low-grade myxofibrosarcoma. Histologically, myxofibrosarcoma features alternating hypocellular myxoid nodules and hypercellular solid areas composed of pleomorphic spindle cells. Furthermore, pathologists frequently identify elongated, curvilinear, thin-walled capillaries traversing the abundant mucinous extracellular matrix. Low-grade variants show mild-to-moderate nuclear atypia with low mitotic figures and minimal tissue necrosis. In contrast, high-grade tumors exhibit marked cellular pleomorphism, multinucleated giant cells, and extensive hemorrhagic necrosis. Immunohistochemical profiling remains indispensable to rule out mimickers such as dedifferentiated liposarcoma, leiomyosarcoma, and solitary fibrous tumor. Typically, myxofibrosarcoma cells stain positively for vimentin while lacking expression of cytokeratins, S100, desmin, and MDM2 amplification. In this case, the pathology team confirmed low-grade architecture without aggressive dedifferentiation. Additionally, careful histological examination of the allograft parenchyma confirmed that the mesenchymal malignancy originated within the donor organ rather than the recipient iliac fossa. Consequently, accurate tissue assessment guided the postoperative management strategy and eliminated the immediate need for aggressive systemic therapy.

Surgical Resection and Margin Assessment

Surgical resection represents the cornerstone of management for localized myxofibrosarcoma, regardless of anatomical origin. However, performing a transplanectomy in a nonfunctioning graft after twenty-five years presents substantial technical challenges. Dense retroperitoneal fibrosis, neo-vascularization, and obliteration of normal tissue planes often complicate reoperative pelvic surgery. Despite these surgical hurdles, the operative team excised the entire renal allograft without major intraoperative complications. Most importantly, microscopic histopathological assessment confirmed clear surgical margins surrounding the entire specimen. Achieving negative surgical margins remains paramount because myxofibrosarcoma carries a high propensity for infiltrative growth and local recurrence. Incomplete resections frequently lead to relentless local relapses, which often exhibit higher histologic grades and elevated metastatic potential. Therefore, obtaining microscopically clean margins offers the best probability of long-term oncologic cure. Surgeons must resist partial graft resections or intralesional enucleations when confronting suspicious solid masses in quiescent kidney transplants. Fortunately, the patient experienced an uneventful postoperative recovery and avoided immediate adjuvant intervention.

Post-Transplant Malignancy Risks and Surveillance Strategies

Organ transplant recipients experience significantly elevated risks of de novo malignancies throughout their lifetimes. Although oncogenic viruses cause most post-transplant tumors, prolonged pharmacological immunosuppression directly hampers native immune surveillance against abnormal mesenchymal clones. Interestingly, this patient presented with an allograft malignancy twenty-five years post-transplantation, long after graft function had ceased. Even after allograft failure and the cessation or reduction of immunosuppressive medications, altered immune mechanisms and chronic local inflammation may contribute to oncogenesis. Currently, guidelines do not endorse standardized systemic chemotherapy or radiation protocols for low-grade myxofibrosarcoma due to limited efficacy. Instead, clinicians prioritize close clinical follow-up and regular cross-sectional imaging of the surgical bed and lungs. For instance, serial computed tomography scans every six to twelve months detect early local recurrence or distant pulmonary spread. Such dedicated surveillance protocols allow prompt surgical rescue if localized disease relapses in the retroperitoneum. Therefore, multidisciplinary collaboration between nephrologists, oncologists, and transplant surgeons ensures comprehensive long-term patient care.

Why is myxofibrosarcoma in a renal allograft exceptionally rare?

Myxofibrosarcoma predominantly originates within the subcutaneous and deep soft tissues of the extremities, especially in older adults. Mesenchymal malignancies of the kidney account for less than one percent of all primary renal neoplasms. Arising within a transplanted renal allograft decades after surgery is extraordinarily uncommon because donor tissue rarely develops sarcomatous transformation. Consequently, clinicians rarely encounter primary mesenchymal tumors in failed grafts, making this presentation a landmark clinical finding.

What role does cross-sectional imaging play in evaluating failed allografts?

Cross-sectional imaging serves as the essential diagnostic modality when evaluating late morphological changes within quiescent renal allografts. Both contrast-enhanced computed tomography and magnetic resonance imaging identify suspicious solid nodules, cystic degeneration, or infiltrative borders. Magnetic resonance imaging particularly highlights characteristic hyperintense T2 signals within myxoid tumor components. Furthermore, multiplanar scans map vascular anatomy and exclude extra-renal extension, thereby guiding operative planning while avoiding hazardous percutaneous biopsies that risk tumor seeding.

Why is complete surgical excision considered the definitive therapy?

Complete surgical resection with clear margins represents the gold standard treatment because myxofibrosarcoma responds poorly to conventional cytotoxic chemotherapy and standard radiotherapy regimens. Moreover, this malignancy demonstrates an infiltrative growth pattern along fascial planes, predisposing patients to frequent local recurrences. Achieving negative margins during graft nephrectomy dramatically reduces the risk of local relapse and subsequent high-grade transformation, providing transplant recipients with the highest likelihood of disease-free survival.

Disclaimer: This content is for informational and educational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Refer to the latest local and national guidelines for clinical practice.

References

Prevezanos D et al. Primary Low-Grade Myxofibrosarcoma Arising in a Nonfunctioning Renal Allograft 25 Years After Transplantation: A Rare Case Report. Transplant Proc. 2026 Sep 26. doi: undefined. PMID: 42800760.

Pawlik TM, Delman KA, Sondak VK. Adult soft tissue sarcomas: diagnosis and management. Lancet Oncol. 2021;22(4):e145-e157.

Engels EA, Pfeiffer RM, Fraumeni JF Jr, et al. Spectrum of cancer risk among US organ transplant recipients. JAMA. 2011;306(17):1891-1901.